-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing…
WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced…
Board-certified providers share guidance on identifying allergy triggers and selecting treatments that align with each patient's symptoms and lifestyle. PHILADELPHIA,…
LAWRENCEVILLE, N.J., Dec. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with…
- EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line…
Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposureFDA denial of Sanofi’s tolebrutinib for nrSPMS shows…
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage…
STAFFORD, Texas, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused…
--Plans to double the Number of Patients in Study-- --Company Expects Initial Findings to be presented in 2026-- BOCA RATON, Fla.,…
Year-End Recap Highlights Breakthrough Discoveries, Platform Advancements, and Strengthened Scientific LeadershipLehi, Utah, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah,…